Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

For patients undergoing jaw reconstruction after surgery for head and neck cancer, computer-aided design and manufacturing ...